Online citations, reference lists, and bibliographies.

Diabetes: Is There A Future For Pharmacogenomics Guided Treatment?

E. Pearson
Published 2019 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Diabetes is a disease defined on the basis of hyperglycemia. There are monogenic forms of diabetes where defining the genetic cause has a dramatic impact on treatment—with patients being able to transition from insulin to sulfonylureas. However, the majority of diabetes is type 2 diabetes. This review outlines the robust evidence accrued to date for pharmacogenetics of metformin, sulfonylureas, thiazolidinediones, and dipeptidyl peptidase‐4 inhibitors but highlights that these variants will only be of clinical utility when the genotype is already known at the point of prescribing. The future of pharmacogenetics in diabetes and other common complex disease relies on a paradigm shift—that of preemptive panel genotyping and use of clinical decision support tools to assimilate this genetic information with other clinical phenotypic data and to present this information simply to the prescriber. Given the recent dramatic fall in genotyping costs, this future is not far off.
This paper references
Pharmacogenomics in diabetes mellitus: insights into drug action and drug discovery
K. Zhou (2016)
Metformin and the gastrointestinal tract
Laura J McCreight (2015)
Metformin alters the gut microbiome of individuals with treatment-naive type 2 diabetes, contributing to the therapeutic effects of the drug
H. Wu (2017)
Disentangling type 2 diabetes and metformin treatment signatures in the human gut microbiota
Kristoffer Forslund (2015)
The systematic application of non-destructive testing techniques for ancient wood buildings
戴俭 (2014)
Variant of transcription factor 7-like 2 (TCF7L2) gene confers risk of type 2 diabetes
Struan F A Grant (2006)
Type 2 diabetes genetic loci informed by multi-trait associations point to disease mechanisms and subtypes: A soft clustering analysis
M. Udler (2018)
Influence of CYP2C9 and CYP2C19 genetic polymorphisms on pharmacokinetics of gliclazide MR in Chinese subjects.
Yifan Zhang (2007)
Novel subgroups of adult-onset diabetes and their association with outcomes: a data-driven cluster analysis of six variables.
E. Ahlqvist (2018)
Association of sulfonylurea receptor 1 genotype with therapeutic response to gliclazide in type 2 diabetes.
H. Zhang (2007)
Activating mutations in the gene encoding the ATP-sensitive potassium-channel subunit Kir6.2 and permanent neonatal diabetes.
A. Gloyn (2004)
Association of Organic Cation Transporter 1 With Intolerance to Metformin in Type 2 Diabetes: A GoDARTS Study
T. Dujic (2014)
Interaction between variants in the CYP2C9 and POR genes and the risk of sulfonylurea‐induced hypoglycaemia: A GoDARTS Study
T. Dujic (2018)
Activating mutations in the ABCC8 gene in neonatal diabetes mellitus.
A. Babenko (2006)
Variation in the Glucose Transporter gene SLC2A2 is associated with glycaemic response to metformin
K. Zhou (2016)
Involvement of organic cation transporter 3 (Oct3/Slc22a3) in the bioavailability and pharmacokinetics of antidiabetic metformin in mice.
Y. Shirasaka (2016)
Repurposing metformin for the prevention of cancer and cancer recurrence
B. Heckman-Stoddard (2017)
Metformin and ageing: improving ageing outcomes beyond glycaemic control
W. Valencia (2017)
PPAR-γ2 and PTPRD gene polymorphisms influence type 2 diabetes patients' response to pioglitazone in China
Qi Pei (2013)
Pharmacogenetics in type 2 diabetes: influence on response to oral hypoglycemic agents
Adem Y. Dawed (2016)
insights into drug action and drug discovery
K. Zhou (2016)
Common polymorphisms of the peroxisome proliferator-activated receptor-gamma (Pro12Ala) and peroxisome proliferator-activated receptor-gamma coactivator-1 (Gly482Ser) and the response to pioglitazone in Chinese patients with type 2 diabetes mellitus.
M. Hsieh (2010)
Effects of Pro12Ala polymorphism of peroxisome proliferator‐activated receptor γ2 gene on rosiglitazone response in type 2 diabetes
E. Kang (2005)
The genetic architecture of type 2 diabetes
C. Fuchsberger (2016)
The CTRB1/2 Locus Affects Diabetes Susceptibility and Treatment via the Incretin Pathway
L. M. 't Hart (2013)
Prevalence of vascular complications among patients with glucokinase mutations and prolonged, mild hyperglycemia.
A. Steele (2014)
Association studies of variants in promoter and coding regions of beta‐cell ATP‐sensitive K‐channel genes SUR1 and Kir6.2 with Type 2 diabetes mellitus (UKPDS 53)
A. Gloyn (2001)
Pharmacogenomic analysis of ATP-sensitive potassium channels coexpressing the common type 2 diabetes risk variants E23K and S1369A
Veronica Lang (2012)
Effects of CYP2C19 and CYP2C9 genetic polymorphisms on the disposition of and blood glucose lowering response to tolbutamide in humans.
J. Shon (2002)
Cross-sectional and longitudinal studies suggest pharmacological treatment used in patients with glucokinase mutations does not alter glycaemia
A. Stride (2013)
T. Dujic (2018)
Association studies of variants in promoter and coding regions of beta- cell ATP- sensitive K- channel genes SUR1 and Kir6.2 with Type 2 diabetes mellitus (UKPDS 53)
Gloyn (2001)
Recessive mutations in the cancer gene Ataxia Telangiectasia Mutated (ATM), at a locus previously associated with metformin response, cause dysglycaemia and insulin resistance
P. Connelly (2016)
Switching from insulin to oral sulfonylureas in patients with diabetes due to Kir6.2 mutations.
E. Pearson (2006)
KCNJ11 E23K variant is associated with the therapeutic effect of sulphonylureas in Chinese type 2 diabetic patients
Q. Li (2014)
influence on response to oral hypoglycemic agents
A. Y. Dawed (2016)
Fine-mapping type 2 diabetes loci to single-variant resolution using high-density imputation and islet-specific epigenome maps
A. Mahajan (2018)
Impact of CYP2C9 amino acid polymorphisms on glyburide kinetics and on the insulin and glucose response in healthy volunteers
J. Kirchheiner (2002)
susceptibil - ity and treatment via the incretin pathway
A. Mahajan (2013)
CYP2C8 and SLCO1B1 Variants and Therapeutic Response to Thiazolidinediones in Patients With Type 2 Diabetes
Adem Y. Dawed (2016)
A soft clustering analysis
Udler (2018)
present clinical challenges
S. Misra (2018)
The CTRB 1 / 2 locus affects
L. M. t Hart (2005)
Cytochrome P450 2C9 *2 and *3 Polymorphisms and the Dose and Effect of Sulfonylurea in Type II Diabetes Mellitus
ML Becker (2008)
Effect of Serotonin Transporter 5-HTTLPR Polymorphism on Gastrointestinal Intolerance to Metformin: A GoDARTS Study
T. Dujic (2016)
The mechanisms of action of metformin
G. Rena (2017)
Ser1369Ala Variant in Sulfonylurea Receptor Gene ABCC8 Is Associated With Antidiabetic Efficacy of Gliclazide in Chinese Type 2 Diabetic Patients
Yan Feng (2008)
TCF7L2 Genetic Variation Augments Incretin Resistance and Influences Response to a Sulfonylurea and Metformin: The Study to Understand the Genetics of the Acute Response to Metformin and Glipizide in Humans (SUGAR-MGH)
S. Srinivasan (2018)
Pharmacokinetics of glimepiride and cytochrome P450 2C9 genetic polymorphisms
R. Wang (2005)
Common variants near ATM are associated with glycemic response to metformin in type 2 diabetes
K. Zhou (2011)
Genetic cause of hyperglycaemia and response to treatment in diabetes
E. Pearson (2003)
Heritability of variation in glycaemic response to metformin: a genome-wide complex trait analysis
K. Zhou (2014)
Genetics of Monogenic Diabetes: Present Clinical Challenges
S. Misra (2018)
HLA-B*5701 screening for hypersensitivity to abacavir.
S. Mallal (2008)
Effect of sulphonylurea treatment on glycaemic control is related to TCF7L2 genotype in patients with type 2 diabetes
Z. Schroner (2011)
Association between TCF7L2 Genotype and Glycemic Control in Diabetic Patients Treated with Gliclazide
M. Javorský (2013)
No deterioration in glycemic control in HNF-1alpha maturity-onset diabetes of the young following transfer from long-term insulin to sulphonylureas.
M. Shepherd (2003)
The Role of Pharmacogenetics in Drug Disposition and Response of Oral Glucose-Lowering Drugs
N. Leeuwen (2013)
Sex and BMI Alter the Benefits and Risks of Sulfonylureas and Thiazolidinediones in Type 2 Diabetes: A Framework for Evaluating Stratification Using Routine Clinical and Individual Trial Data
J. Dennis (2018)

This paper is referenced by
Semantic Scholar Logo Some data provided by SemanticScholar